Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ...

Shares of Hims & Hers plunged over 30% after Wegovy maker Novo Nordisk abruptly ended their partnership on Monday, accusing ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Weaver outlined her concerns with counterfeit weight-loss medication. “If there is, contaminants, allergens in it, that sort ...

Get CBS19 news on-demand by downloading the free CBS19+ app available on ROKU, Amazon Fire and Apple TV!

Indeed, Novo Nordisk, the developers of Ozempic and Wegovy, are currently conducting two large-scale trials testing semaglutide for Alzheimer’s (both are expected to conclude as early as this year).

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.